Table 1.
Descriptive table of 209 HNSCC patients stratified by metabolic subtypes A and B derived from hierarchical clustering of 186 plasma metabolites.
| All (N = 209) |
Subtype A (N = 86) |
Subtype B (N = 123) |
p Value | ||
|---|---|---|---|---|---|
| Age | mean (SD) | 59.3 (10.1) | 61.7 (10.3) | 57.6 (9.7) | 0.004 |
| BMI | mean (SD) | 27.5 (5.2) | 28.1 (5.8) | 27.1 (4.7) | 0.18 |
| Sex | Male | 156 (75%) | 65 (76%) | 91 (74%) | 0.92 |
| Female | 53 (25%) | 21 (24%) | 32 (26%) | ||
| Race | White | 170 (81%) | 73 (85%) | 97 (79%) | 0.36 |
| Black | 39 (19%) | 13 (15%) | 26 (21%) | ||
| HPV status | Negative | 108 (52%) | 43 (50%) | 65 (53%) | 0.79 |
| Positive | 101 (48%) | 43 (50%) | 58 (47%) | ||
| Smoking history | Never | 81 (39%) | 33 (39%) | 48 (39%) | 0.83 |
| Former | 67 (33%) | 29 (35%) | 38 (31%) | ||
| Current | 58 (28%) | 22 (26%) | 36 (30%) | ||
| Alcohol | <1 drink/week | 114 (55%) | 47 (55%) | 67 (55%) | 0.99 |
| 1+ drink/week | 92 (45%) | 38 (45%) | 54 (45%) | ||
| Marital status | Married or partnered | 148 (71%) | 62 (72%) | 86 (70%) | 0.85 |
| Single | 61 (29%) | 24 (28%) | 37 (30%) | ||
| Tumor site | Oropharynx | 106 (51%) | 45 (53%) | 61 (50%) | 0.56 |
| Oral cavity | 31 (15%) | 12 (14%) | 19 (15%) | ||
| Larynx | 35 (17%) | 11 (13%) | 24 (20%) | ||
| Other | 36 (17%) | 17 (20%) | 19 (15%) | ||
| Tumor stage * | I | 10 (5%) | 5 (6%) | 5 (4%) | 0.77 |
| II | 16 (8%) | 5 (6%) | 11 (9%) | ||
| III | 83 (40%) | 36 (42%) | 47 (39%) | ||
| IV | 98 (47%) | 40 (47%) | 58 (48%) | ||
| T | 1 | 37 (18%) | 19 (22%) | 18 (15%) | 0.43 |
| 2 | 51 (25%) | 20 (24%) | 31 (26%) | ||
| 3 | 47 (23%) | 21 (25%) | 26 (22%) | ||
| 4 | 70 (34%) | 25 (29%) | 45 (37%) | ||
| N | 0 | 46 (22%) | 18 (21%) | 28 (23%) | 0.09 |
| 1 | 22 (11%) | 4 (5%) | 18 (15%) | ||
| 2 | 130 (63%) | 60 (70%) | 70 (58%) | ||
| 3 | 8 (4%) | 4 (5%) | 4 (3%) | ||
| Treatment | Radiotherapy | 45 (22%) | 20 (23%) | 25 (20%) | 0.87 |
| Chemoradiotherapy with Cisplatin | 118 (56%) | 48 (56%) | 70 (57%) | ||
| Chemoradiotherapy with Carboplatin and Paclitaxel | 46 (22%) | 18 (21%) | 28 (23%) | ||
| Feeding tube | No | 80 (40%) | 35 (43%) | 45 (39%) | 0.60 |
| Yes | 118 (60%) | 46 (57%) | 72 (62%) | ||
| ECOG performance | Active | 100 (50%) | 39 (48%) | 61 (52%) | 0.89 |
| Restricted | 73 (37%) | 31 (38%) | 42 (36%) | ||
| Non-working | 26 (13%) | 11 (14%) | 15 (13%) | ||
| Prior comorbidity | Yes | 154 (75%) | 66 (77%) | 88 (73%) | 0.69 |
| No | 52 (25%) | 20 (23%) | 32 (27%) | ||
| Albumin | mean (SD) | 3.95 (0.42) | 3.97 (0.39) | 3.94 (0.43) | 0.60 |
| Hemoglobin | mean (SD) | 13.18 (1.80) | 13.22 (1.71) | 13.15 (1.87) | 0.80 |
| Neutrophil-to-lymphocyte ratio | mean (SD) | 3.18 (2.07) | 3.32 (1.98) | 3.08 (2.13) | 0.45 |
| Platelet-to-lymphocyte ratio | mean (SD) | 170,347 (98,859) | 161,891 (64,755) | 176,207 (116,774) | 0.35 |
HNSCC = head and neck squamous cell carcinoma, BMI = body mass index, HPV = human papillomavirus, ECOG = Eastern Cooperative Oncology Group, SD = standard deviation. * Using the 8th edition of the American Joint Committee on Cancer Tumor Staging by Site.